| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0003 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.2 | 0.0003 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0004 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0004 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.26 | 0.0005 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0006 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.26 | 0.0006 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0006 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.21 | 0.0008 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.2 | 0.0008 |